Inspire Medical Systems (INSP) vs Tandem Diabetes Care (TNDM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Tandem Diabetes Care (TNDM) has outperformed Inspire Medical Systems (INSP) over the past year, losing 18.0% versus a loss of 38.7%. Over five years, INSP leads with a -75.9% price change compared with -86.5% for TNDM. Inspire Medical Systems is the larger company by market cap ($1.60 billion vs $1.22 billion), about 1.3 times the size.
On valuation, Inspire Medical Systems trades at a lower forward P/E (36.8x vs 195.5x for Tandem Diabetes Care). Inspire Medical Systems converts more of its revenue into profit, with a net margin of 15.9% versus -20.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INSP | TNDM |
|---|---|---|
| Share price | $55.10 | $17.46 |
| Market cap | $1.60B | $1.22B |
| 1-day change | -2.10% | +3.93% |
| YTD return | -40.26% | -20.56% |
| 1-year return | -38.69% | -17.95% |
| 5-year return | -75.91% | -86.53% |
| P/E ratio (TTM) | 16.45 | — |
| Forward P/E | 36.85 | 195.48 |
| EPS (TTM) | $3.35 | $-0.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $911.98M | $1.01B |
| Revenue growth (YoY) | +13.60% | +7.93% |
| Net income (latest FY) | $145.42M | $-204.71M |
| Gross margin | 85.39% | 53.81% |
| Operating margin | 5.59% | -18.45% |
| Net margin | 15.95% | -20.17% |
| 52-week high | $147.03 | $29.65 |
| 52-week low | $38.91 | $12.26 |
| Distance from 52-week high | -62.52% | -41.11% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +25.92% | +55.21% |
| Average volume | 765.67K | 2.26M |
| Shares outstanding | 28.97M | 69.79M |
| Employees | 1,333 | 2,500 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TNDM has outperformed INSP by 20.7 percentage points over the past year.
- Inspire Medical Systems is more profitable, keeping 15.9 cents of every revenue dollar as net income versus -20.2 cents for Tandem Diabetes Care.
- Inspire Medical Systems grew revenue faster in its latest fiscal year (+13.60% vs +7.93%).
About Inspire Medical Systems
INSP stock →Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for patients with moderate to severe OSA.
Health Care · Medical/Dental Instruments · 1,333 employees
About Tandem Diabetes Care
TNDM stock →Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally.
Health Care · Medical/Dental Instruments · 2,500 employees
INSP vs TNDM FAQ
Which is bigger, Inspire Medical Systems or Tandem Diabetes Care?
Inspire Medical Systems (INSP) is larger, with a market capitalization of $1.60B compared with $1.22B for Tandem Diabetes Care (TNDM).
Which stock has performed better over the past year, INSP or TNDM?
TNDM returned -17.95% over the past 12 months, compared with -38.69% for INSP (price return, excluding dividends). Past performance does not predict future results.
Are Inspire Medical Systems and Tandem Diabetes Care in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.